Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, but it remains unlicensed in the UK and is only available within regulated clinical trials
Microdosingessentially, taking a smaller dose of something than is normally prescribedhas taken off among some users of GLP-1 medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro)
Learn more: What is Zepbound
Analysis of FAERS data from 2004 to 2020 revealed significant associations between GLP-1 RA and various neoplasms, notably medullary thyroid cancer (PRR, 27.43), papillary thyroid cancer (PRR, 8.68), malignant pancreatic neoplasms (PRR, 9.86), and pancreatic neuroendocrine neoplasms (PRR, 2.86) [52]